Evidence map›Paper›PMID 32245383›Full record

ArticleBMC medical genomics2020

Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL.

Monika Lejman, Monika Włodarczyk, Joanna Zawitkowska, Jerzy R Kowalczyk

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC medical genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Monika LejmanLaboratory of Genetic Diagnostics, Department of Pediatric Hematology, Oncology, and Transplantology, Medical University of Lublin, ul. Antoniego Gębali 6, Lublin, Poland. lejmanm@poczta.onet.pl.ORCID 0000-0002-8760-0775
Monika WłodarczykLaboratory of Genetic Diagnostics, Medical University of Lublin, Lublin, Poland.ORCID 0000-0001-8326-4818
Joanna ZawitkowskaDepartment of Pediatric Hematology, Oncology, and Transplantology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0001-7207-156X
Jerzy R KowalczykDepartment of Pediatric Hematology, Oncology, and Transplantology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0003-3080-0845
Medical University of Lublin · PL

Funding

STRATEGMED STRATEGMED3/304586/5/NCBR/2017
6 · The paper itself

Abstract

backgroundThe use of high-throughput analytical techniques has enabled the description of acute lymphoblastic leukaemia (ALL) subtypes. The TCF3-HLF translocation is a very rare rearrangement in ALL that is associated with an extremely poor prognosis. The TCF3-HLF fusion gene in the described case resulted in the fusion of the homeobox-related gene of TCF3 to the leucine zipper domain of HLF. The TCF3-HLF fusion gene product acts as a transcriptional factor leading to the dedifferentiation of mature B lymphocytes into an immature state (lymphoid stem cells). This process initiates the formation of pre-leukaemic cells. Due to the rarity of this chromosomal aberration, only a few cases have been described in the literature. The advantage of this work is the presentation of an interesting case of clonal evolution of cancer cells and the cumulative implications (diagnostic and prognostic) of the patient's genetic alterations. CASE PRESENTATION: This work presents a patient with diagnosed with TCF3-HLF-positive ALL. Moreover, the additional genetic alterations, which play a key role in the pathogenesis of ALL, were detected in this patient: deletion of a fragment from the long arm of chromosome 13 (13q12.2-q21.1) containing the RB1 gene, intragenic deletions within the PAX5 gene and NOTCH1 intragenic duplication.

conclusionsA patient with coexistence of chromosomal alterations and the TCF3-HLF fusion has not yet been described. Identifying all these chromosomal aberrations at the time of diagnosis could be sufficient to determine the cumulative effects of the described deletions on the activity of other oncogenes or tumour suppressors, as well as on the clinical course of the disease. On the other hand, complex changes in the patient's karyotype and clonal evolution of cancer cells call into question the effectiveness of experimental therapy.

Indexed as

Translocation, GeneticAdolescentChromosomes, Human, Pair 17Chromosomes, Human, Pair 19FemaleHumansOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrognosisOncogene Proteins, FusionTCF3-HLF fusion protein, humanAcute lymphoblastic leukaemiaCase reportGene fusionMolecular abnormalitiesRB1TCF3-HLF

Identifiers

PMID32245383
PMCPMC7118981
OpenAlexW3014547381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.